Patents by Inventor Marc GODINAT

Marc GODINAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11634488
    Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: April 25, 2023
    Assignee: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH
    Inventors: Claudine Vermot-Desroches, Chanthy Kong-Flohr, Marc Godinat, Bruno Cavallini
  • Publication number: 20220227862
    Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
    Type: Application
    Filed: July 10, 2018
    Publication date: July 21, 2022
    Inventors: Claudine VERMOT-DESROCHES, Chanthy KONG-FLOHR, Marc GODINAT, Bruno CAVALLINI